Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 12/20 | 0.54 |
| ▸ | ELANE | P08246 | 8/20 | 0.52 |
| ▸ | CTRC | Q99895 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8092357 | 0.85 | CMA1 (0.58) | CMA1ELANE | |
| SCHEMBL10081595 | 0.81 | ELANE (0.65) | CMA1ELANE | |
| SCHEMBL6803099 | 0.81 | ELANE (0.44) | CMA1ELANE | |
| SCHEMBL13036082 | 0.81 | CMA1 (0.56) | CMA1ELANE | |
| SCHEMBL6282998 | 0.80 | CTSB (0.56) | — | |
| SCHEMBL13036085 | 0.79 | CMA1 (0.55) | CMA1ELANE | |
| SCHEMBL7664531 | 0.79 | CAPN1 (0.48) | CMA1ELANE | |
| SCHEMBL30688542 | 0.79 | CMA1 (0.68) | CMA1ELANECTRC | |
| SCHEMBL10081596 | 0.79 | ELANE (0.57) | CMA1ELANE | |
| SCHEMBL17425092 | 0.78 | CMA1 (0.56) | CMA1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852744-B2 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | CMA1, CTRL, TPSD1 | CMA1 1/4885ELANE 634/4885CTRC 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.